ClinicalTrials.govpublic full text
Open Label Extension to Bridging Study CTBM100C2303
pseudomonas aeruginosa, cystic fibrosis, tobramycin inhalation powder, lung diseases, anti-bacterial agents, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 832901
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.